2023-07-18 05:42:11 ET
- Mainz Biomed ( NASDAQ: MYNZ ) entered commercial partnership for ColoAlert with Fugene Genetics, a renowned genetic testing service provider based in Israel.
- Fugene Genetics, established in 2008, offers a wide range of advanced genetic testing services to private clients, health organizations, hospitals, and genetic institutes throughout the country.
- "This partnership aligns with our commitment to delivering cutting-edge genetic testing solutions and improving healthcare outcomes. We are excited about the opportunity to work closely with Mainz Biomed to ensure a successful commercial launch and make a significant impact on colon cancer screening in Israel.” said Noa Rinzler Diwan, PhD, CEO of Fugene Genetics.
For further details see:
Mainz Biomed joins hand with Fugene Genetics in Israel